AnteoTech Limited (ADO) Earnings Call Transcript & Summary

March 1, 2026

Australian Securities Exchange AU Materials Chemicals earnings 37 min

Earnings Call Speaker Segments

Simon Hinsley

unknown
#1

Morning, everyone, and thanks for joining AnteoTech's investor briefing after we released our first-half Financial Year 2026 report. With us is Managing Director and CEO Merrill Gray, who'll walk through the presentation that's up on the screen. A quick reminder that quite a few questions came in ahead of time. If there's room to get through them, we'll take a handful more via the Q&A button at the bottom of the screen. So with that, Merrill, over to you. Thanks.

Merrill Gray

executive
#2

Thanks so much, Simon. To start, I want to express my appreciation to all of you for joining and for spending the time to review our half yearly results. I've also put into the presentation a brief forward look at where we stand today and the direction we're taking. So we'll go through the next few slides. And yes. Okay. So to sum up the half year, we have, as I mentioned, a reset of the cost base structure. We've basically positioned the company so that we're both streamlined and sharply focused on everything shareholders are asking of us, which is conversion of sales along with strategic partnerships, and I'll get to the sales pipeline a bit later in the presentation and cover the half yearlies by looking back first. During that period, there have been several key developments for the company. And that has come about essentially as a far great -- as a result of much greater market segmentation and real focus on the value proposition and the offerings we provide to customers. So as you can see, Ultranode X, which many shareholders were very pleased to see the results achieved there, and I have a bit more about our joint product with BDS, which has -- we -- I've already said later in this presentation that we intend to have the first of those beta samples of that product by the end of this week.

Merrill Gray

executive
#3

And we've discovered that Anteo S is seeing significant market demand when it comes to ceramic-coated separators. Then, naturally, there's the life sciences area. A great deal of work has been completed there, and I'm fairly enthusiastic about walking through some of it during this presentation. So overall, in reflection, we've built a very strong foundation to move ahead. We completed the $3.5 million capital raise, and that has provided us with runway to deliver on the items in our pipeline, which I'll discuss further. Next slide, please. So on this slide here, if you exclude the Serum Institute revenues — that's the pink box — and naturally, those revenues come in roughly every 6 months, but what happened during the half year was that we didn't receive — we got the order, yet we didn't dispatch it, and we couldn't recognize the revenue for the Serum Institute. So — but if you look at a reconciliation between where we stood at this time last year in terms of the half yearly results and where we sit now, as you can see, a considerable amount of effort is going into really streamlining the business and ensuring the organization stays very focused and essentially does what's truly critical and achieves more with less.

Merrill Gray

executive
#4

And over on the right-hand side, you can see a number of the things that have been accomplished. Let's go to the next slide, please. This table comes directly from the half yearly report and presents that data in a similar way. And once again, another comparison regarding where our changes in operating cost have occurred. The following slide deals with revenue, which I know has prompted quite a few questions, and I'll talk a bit more about our revenue and the potential revenue coming forward. Naturally, I'm not in a position to give sales projections. Next one, please. But what I can tell you — this slide is actually month by month on samples dispatched. And at the top, you can see I've restated, as we've discussed with many shareholders, the actual sales — the structured sales process that we go through. And what's pretty — what's really important, obviously, is the evaluation and feedback stage. And when I get to some of the — where we stand in the pipeline for our business units, that's really where a lot of this half year has really — the timing has really been spent, along with sales negotiations. And I know there's a level — can you go faster.

Merrill Gray

executive
#5

We're putting effort into improving how we communicate, staying highly focused on the people we reach out to, and ensuring we have sales and marketing professionals backing up the technical business units. I'm really happy about this, and we'll be glad to walk through where that has taken us up to now. Next slide, please. So let's go through this slide on what the battery business has accomplished. As I mentioned, with BDS we now have a formulation along with 6 potential customers identified, and everything is being handled via our U.S. partner, Black Diamond Structures, which, since it's located in the U.S., can take care of the logistics of shipping samples out, and we really look forward to that. The team has promised me that samples are being sent out this week, and I look forward to giving an update on that through social media. On Wyon, I have a bit more to share later in the presentation, so I'll return to that. But progress is happening, and in fact sales are being put together in the miniature Wyon cell design. That's a fairly significant step forward. They've actually progressed from coin cells to their own battery design.

Merrill Gray

executive
#6

And we’re highly focused on making sure shareholders are kept informed whenever Wyon delivers material results to us. I want to note that next week we’ll be in South Korea, in front of prospective customers who have gotten samples and are already testing them. We’ll be there alongside Kangshin as part of the InterBattery conference. That’s a bit of — that’s the way we’re progressing when it comes to ensuring we’re highly targeted about which conferences we attend, which leads we take on, and the structured process we use to move those leads along. So Kangshin, our distributor in South Korea, will be with us throughout that conference, during the time we’re in South Korea. And we’ve specifically asked Austrade for support to help us reach additional customers that fall outside Kangshin’s distributorship. So I’m looking forward to updating everyone on that too. And then, naturally, Ultranode. Development of Ultranode keeps moving quickly, very much in line with where it will ultimately land as a product. And we are very — really — it’s genuinely exciting for us to be in front of 2 companies that are actually battery manufacturers and to try to negotiate getting Ultranode in as a next-generation anode for drones.

Merrill Gray

executive
#7

We specifically zeroed in on those manufacturers since they either already produce goods or will have plants opening shortly. That means we must establish a presence and secure a stake in their upcoming products. Let's move to the next slide. Turning to Life Sciences, this unit has been extremely active and achieved a lot of success across several areas. Naturally, our partnership with Serum Institute is still being handled, and the unit's leader recently met with them over in India, and they took away prototypes of some new offerings. So we keep working to make that connection as robust as we can. Beyond that, there are additional items in development, and we would like to believe significant developments are on the horizon, but I want to state plainly that we are — whatever updates arise will be made public. What we can say is that we have been in discussions with several other firms that we have dealt with previously and maintain ties to, and since they know our products, that simplifies matters considerably. All right. So the crucial point regarding Life Sciences is that AnteoBind is applicable across multiple end users for diagnostics.

Merrill Gray

executive
#8

So while lateral flow and Luminex have been areas of focus for us, chemiluminescence and ELISA plates are where work has been carried out. And we've actually been putting together a comparison — a paper that lays out how AnteoBind performs in chemiluminescence side by side — and we've made really solid progress toward getting that published in the very near future. So we're looking forward to that. So yes, I think we'll move to the next slide. Just wanted to — that's really the crux of it for the half yearly. So it comes down to getting everything in order. We will, of course, keep driving continuous improvement, making sure every person on the team stays sharply focused on the bottom line and understands what they need to do to deliver, and getting ourselves financially into a position where we're able to deliver. So next slide, please. That all revolves around the strategy we released, which centered on making sure we're present in jurisdictions that are ready and genuinely receptive to the technologies and products we have. So whether that's South Korea, given its leadership in battery manufacturing, or the U.S., particularly when it comes to drones and the opportunities emerging there with very significant growth profiles, or whether it's India, of course.

Merrill Gray

executive
#9

India does bring certain complications and challenges along with it, and I’ll get to those on a different slide. So, continuing on, here’s a quick snapshot for anyone who’s new. This is the way we now present our offerings for the battery business. So all of you know Anteo X. On the left there is Anteo S, our separated product, which remains at the trial stage but is with several customers for trialing. So we’re very much looking forward to the feedback, especially when we are in South Korea on that. And then SiMRAX, which is a beta test name for the joint product we have developed together with Black Diamond Structures. Next slide, please. What I’d say about all of those products is that — what has mattered greatly for us in growing the quantity of samples we’ve been able to send out and the real interest in our products has been ensuring we communicate at all times the advantages of our products to our customers, whether that’s better battery performance, whether that’s a reduction in cost across their overall manufacturing, or whether that’s ease of use, and that carries high value.

Merrill Gray

executive
#10

And regardless of the business unit in question—batteries or life sciences—that's what our products deliver. On the other side, the battery business has been advancing quite well too—making meaningful headway, especially when it comes to demonstrating to prospective partners just how far the technology has progressed and how well it performs across different applications. So the following slide—actually the next few slides are included here because I believe our shareholders would find them genuinely interesting. Naturally, people understand—well, our shareholders do—but what's truly essential for us in the broader market is that people grasp how Ultranode stacks up against other products on offer. That's precisely what these partnerships we're pursuing are designed to do. We have to communicate how advantageous it is, especially at commercial scale, from a supply chain standpoint and from the standpoint of lowest-cost production. Micro silicon compares favorably against some rather costly and highly complicated alternatives. Next slide, please. And this one really pulls things together with specifics on applications. And I'd say, as I mentioned before, this is really the heart of what we're after—making sure the customers, the prospective customers we're engaging with.

Merrill Gray

executive
#11

We are extremely clear about the points where we can contribute value to the finished products. And therefore their sales and our sales. So with regard to Ultranode 95, once more, there are quite a few assumptions embedded here, yet what matters greatly is the power, the potential power that Ultranode is able to deliver in combination, naturally, with the cathode and the overall cell design, and then the potential, as you can see, for that space and volume to be 2 to 3x thinner. So these things are essential, naturally, for drones and how drones -- the duties that drones perform when it comes to taking off with payload, the distance they must cover. And this really is part of our moving into a joint development with makers of batteries for drones. Okay. Thank you. So returning somewhat to what -- to the progress achieved during the last 6 months regarding Black Diamond Structures and Ultranode. So we -- what appears at the bottom left of this page is our beta testing flyer that we must use to engage with prospective customers. And we have gone through it as a team, operating under their collaborative joint development agreement.

Merrill Gray

executive
#12

As a team, we've focused on ensuring everything gets done so that customers' experience with the trial samples is as positive as it can be. On the Ultranode side, there have been moves in the right direction, and people's frustration around Wyon has been conveyed to me — that effort is basically progressing well. It's very slow, but it is progressing well. The moves concern commercial scale and the ability to scale up. They concern the quality of Ultranode going into batteries for testing and now the quality of anode going into Wyon's specific cell design as the anode. So we genuinely look forward to when we can, as soon as we can, get information from Wyon, which of course is running the test, that has been supplied to us, so we can supply information to shareholders. Thank you. So again, just to wrap up on batteries. This is where we stand regarding the very specific, very targeted pipeline we have been building over the last 6 months. And of course, those lead indicators — the samples being out for testing, the test results coming back, and the sales negotiations — are the nitty-gritty that people expect us to handle. So here, we have sales qualified leads and a number of samples for dispatch under negotiation.

Merrill Gray

executive
#13

So then, looking at all our products — Anteo X, Anteo S, and I’ve wrapped up SiMRAX here — plus Ultranode, considering what we have with prospective customers and what’s actually in negotiation. As I mentioned before, we use conferences in a very targeted way, especially where we receive backing. In South Korea, for instance, Austrade supports us. They provide a booth — we don’t cover the cost of it — but we can bring people in to meet with us and arrange pre-meetings, which is where the team’s attention is. So we’re genuinely looking forward to it. In the U.S., the second-largest conference is coming at the end of March. We’ve already begun outreach about our products ahead of it and anticipate productive meetings there. Thank you. Right. Turning to our Life Sciences business — many of you have seen this slide previously. The main point is on the left side regarding Multiplex activation kits. What we sell to the Serum Institute and how they apply it isn’t something every company can do — in fact, only a small share of the market is able to use our product that way, and the team recognizes that.

Merrill Gray

executive
#14

What that has meant, then, is that developments have taken place regarding which other immunoassays and IVD applications AnteoBind could work in successfully. And that is where the efforts in chemiluminescence and activating particles, and then ELISA plates, come in — making sure ELISA plates can be activated cost effectively and that a low-cost product which performs well is available to customers. The middle one is a space that is truly next generation and where we also see enormous potential. And that really sits on the Biosensor side of things. And really, the graphic at the bottom illustrates someone with a sensor worn on their skin, containing AnteoBind, able to communicate with their phone — which would detect traces related to heart attack. That is how sensitive things are becoming and how interactive things are becoming, and obviously being part of the MOBIUS research group — research institute is part of our involvement in that kind of area, that sector. Now, I have given information before on the overall market around lateral flow and Luminex, as well as chemiluminescence and ELISA plates. So please — go and refer to my earlier presentations on how the market is structured. But that really opens us up to more than USD 30 billion in market value, of which we are talking about activated beads, which is only one part of that.

Merrill Gray

executive
#15

But this represents a really substantial widening of what our life sciences market can be. All right, let's go to the next one, please. So once more, when it comes to the opportunity pipeline and the direction everything is heading for the business, there is a very strong emphasis on a structured process, with sales and marketing personnel backing the technical team and bringing samples through — additional samples are out and have been for a while, and we're extremely pleased and excited about where we might get to. Next one. So really, to sum up, the main points I want to leave with you today concern the reality that we have runway and that we have the funds to deliver. Now let's be clear, we understand that sales conversion is completely critical to our shareholders. And we believe we've put ourselves in a position where we can deliver on that. And I can definitely assure you that every effort is going into doing so. Each and every day, the team is concentrated on how we can advance sales conversion and grow our sales. So people, processes, plans and opportunities — those are what we've worked on, and those are what are now beginning to be in place and coming through.

Merrill Gray

executive
#16

All in all, I'd say our position going into the future is quite strong. I also want to express my appreciation to everyone for the interest you've shown and for the continued backing you give the company, and I genuinely can't wait to collaborate with the team and push everything ahead in the manner that's expected of us. Now I'm ready for questions, Simon.

Simon Hinsley

unknown
#17

Merrill. We’ll move on to the questions submitted in advance, as outlined in the ASX announcement. Perhaps to start, regarding Anteo’s slower progress toward sales contracts in clean energy. One case is Wyon, which has come up before in past updates and quarterly reports, and the refrain has consistently been that additional testing is required. Please give us an update on when we should expect movement on Wyon. And at what point is testing sufficient?

Merrill Gray

executive
#18

Yes, that makes sense to me, and I respect it. So we do have a dedicated team that works alongside the Wyon team. Update meetings happen every two weeks, and there's a structured program for Wyon to work through and then release the results of their testing. So all of us are looking forward to that, so that we can make it — we can make it public. Of course, that's what we expect, and we're trying to manage it so that it turns out as positive as possible. So I certainly get the frustration. But what we've spent time on is bringing that to — trying to bring that to fruition, if you like, though it does highlight that we need more. Wyon is one, and we need additional people testing. Ultranode, whether that's Ultranode 70, 95 or Ultranode X. We need more in the pipeline so we can positively test with an end application, and that is the critical piece. We're really focused on that in the U.S. with what we're doing with Ultranode 95. I go — I guess the bottom line for me is that we are making progress. It's frustratingly slow, but we're clear on the need to bring that to fruition.

Merrill Gray

executive
#19

However, since Wyon operates it, the data comes to us on the receiving side, though that team handles it.

Simon Hinsley

unknown
#20

I just have one question about the sales team and the executives. Could you give us an update on how you're measuring success on the sales side?

Merrill Gray

executive
#21

That's a great question. Yes. So obviously we are monitoring sales at a very detailed level. And we're increasingly making use of the CRM, and that's largely because we've brought on 2 professional salespeople who really require and grasp how the CRM gets used, and who will collaborate with each of the businesses. But when it comes to metrics — first of all, we do have, of course, targets, budgets, and forecasts that we're striving to hit. And everyone knows about them. So all of them are aware. Each person also has individual KPIs, a significant share of which relate to sales. And beyond that, we're actually launching a program focused on celebrating sales. So in the office, it's about ensuring we celebrate and record it when sales come in, so that the structured process people are now mastering and comprehending shows them the end result. So I suppose there's a bit of culture involved, if you like, along with the metrics. We — the way contracts are structured, obviously it's fairly standard across the industry for sales targets to exist for the sales professionals, and that is the situation here.

Simon Hinsley

unknown
#22

Just a question about the site. When should we expect a new website to appear?

Merrill Gray

executive
#23

All right, thank you for asking. So, one of the salespeople we recently brought on board has been tasked with obtaining quotes for a brand-new website. We therefore need to be certain that whatever we end up with suits the purpose of where the business is headed. Simply swapping things around and making small adjustments won't cut it. So essentially, we have to produce a briefing paper first, which will let us go out and seek quotes. That should really be done before this financial year closes. Doing the job properly is very much my preference. He feels the same way, and input will be gathered along the way. I'm certain plenty of people will want to contribute their ideas, but right now we are in the middle of designing it and seeking quotes for it.

Simon Hinsley

unknown
#24

And just a question about the capital raising. Obviously, the stock — which is outside your control — is trading below the level of the most recent capital raising. I just want to ask what we're doing, or how we can fix the share price going forward.

Merrill Gray

executive
#25

Yes, I follow that question. What I've consistently said is that everything hinges on the progress we achieve in the business and the news that comes our way — the flow of news arriving. Now, I've discussed the progress covered in this presentation, which we've been putting hard work into. That includes the new product launched in the U.S. and our understanding of what's possible for us in the chemiluminescence space. We've also signaled that there's work we intend to carry out with a very large Life Sciences business. And we're awaiting the finalization of some commercial arrangements or negotiations. So my response is that we must demonstrate that everything we've discussed is reaching fruition. And my response is that we actually need to accomplish everything we've committed to doing in a structured, focused and cost-effective manner. And we are very, very much striving to do exactly that. And we need to be mindful of some of our customers — some are very large, and some face their own difficulties because they too are raising funds. So we're proceeding along the path of ensuring we have very strong customer engagement, and that we can convert as soon as possible.

Merrill Gray

executive
#26

On the sales side, that person truly gets that journey. For me, news flow is essential if I’m going to deliver genuine progress that I can announce to the market. As for strategic partnerships, we do see certain opportunities, though the formal program around that is only now beginning, with a few conversations in the U.S. Understanding where we would fit is a fairly important piece of that. We’ve done some work. We know what we have, and we believe we understand how we might draw people toward what the business offers, but it will take a lot of hard work, engagement, feedback, and then trying again. So my answer is this: it comes down to doing what we said we would do, making things happen, and making it clear in the marketplace that we are making progress.

Simon Hinsley

unknown
#27

We still have a few more questions to get through. This one is about whether there have been any talks regarding a sale of AnteoTech's IP to parties that might be interested, given that there aren't any solid revenue-generating deals at present.

Merrill Gray

executive
#28

Actually, a contract does exist. I believe it has been with Thermo Fisher for just 15 years, and that was a licensing agreement. That is probably a fact that isn't widely known, but the answer is that nothing is off the table. And in certain of the negotiations, we are discussing what we might expect, though it has to be driven by evidence—by us having a strong product that customers want to purchase, which could result in licensing arrangements. So the response to that question is that all of it is embedded in the kinds of conversations we are having. We are examining every opportunity for revenue for the business and returns to shareholders.

Simon Hinsley

unknown
#29

Could you rank the products, or point out the top three, by how prospective they are — meaning how near they are to bringing in revenue? And where do the drying battery manufacturers fit in that ranking?

Merrill Gray

executive
#30

That applies only to batteries. Am I understanding correctly that it's specifically about batteries?

Simon Hinsley

unknown
#31

Yeah, I believe that's the case. So let's address that point.

Merrill Gray

executive
#32

Yes. Yes. That's a really good question as well. Naturally, Ultranode is a complete formulation, correct? And the way we could deliver into that — whether we toll it, since we had a contractor manufacturing our product, or whether we license it in. As an anode, we sit much further along the value chain than we do with a drop-in product, okay? And the reason I raised that question at the start is that the same holds for Life Sciences. If you're essentially an additive or a performance enhancer in natural flow, where do you stand if you're an activator of particle and chemiluminescence? You're shifting along the value chain to become a core ingredient. So going back to batteries, it's really crucial to grasp that anode — Ultranode is a complete anode formulation. And then our products, our products, so Anteo X and Anteo S are — well, Anteo X is the one where we've spent money and invested heavily in communicating what it can do. We've clearly done work with Black Diamond Structures to demonstrate that it can truly add value through improving performance and reducing very expensive carbon nanotubes. So very good information on what it can do for our customers.

Merrill Gray

executive
#33

A great deal of work has gone into this. The team has also recognized that, in essence, a variant of Anteo X is applicable to separators, and separators are found in every battery. So they are being quite careful about grasping which markets we operate in and how to accelerate progress across those different markets. So yes, I would say that in fact a substantial share of our samples are for Anteo X, which would come as no surprise to the battery team, and we are putting considerable effort into sourcing, into pursuing new technical channels of communication, to ensure we are reaching the decision makers who could either adopt Anteo X or SiMRAX, which might be the option they prefer.

Simon Hinsley

unknown
#34

Merrill, a quick question about battery tech. In Australia it's tough to get over the finish line. If somebody signs a supply contract, what has to happen? And is the company actually going to supply now?

Merrill Gray

executive
#35

Yes. Yes. So regarding the products. On the product side, yes, we are. As much — we do have — obviously, we have a facility, the pilot plant, and we're able to — it depends on the volume for Anteo X. It's a good question because whilst our focus is in the jurisdictions we've identified through the strategy framework around the U.S., South Korea, India and Europe, of course, we keep an eye on, but that's where we see things moving around leading technologies. So I guess the key thing is making sure that we are ready. I have been doing quite a lot of work with the team on export readiness because each of those jurisdictions requires a number of regulations to be met, not only for import, but also for distribution of product. So we are ready for the jurisdictions, which are very much outside of Australia, what we are getting ourselves ready. There's more work to be done, but we have plans for that. When it comes to Australia, of course, that is not our biggest — that is not our focus. But what we have done in the last 6 months is we have gotten ourselves more familiar with the ecosystem.

Merrill Gray

executive
#36

There are plenty of excellent Australian businesses doing genuinely impressive work. We've held discussions with some of them regarding possible collaboration—be it a drone maker that may be supplying the Australian Defence Force and wants to enter the U.S. market, or firms producing specialized, custom batteries or battery management systems. We feel quite optimistic about our ability to partner with outstanding, highly inventive Australian companies. We're currently figuring out the best way to proceed in cases where it's sensible and keeps costs reasonable for all involved. So to answer directly: our primary focus lies beyond Australia. We need to place our sample volumes and our volumes where we intend to sell. That's what we're doing. At the same time, Australia's ecosystem and its innovation base are quite robust, and we're glad to be involved and to be developing these relationships.

Simon Hinsley

unknown
#37

One final question: what would you say to current investors or someone considering becoming a shareholder to explain what has changed across the years, and why now could be the moment to invest in or take a look at AnteoTech?

Merrill Gray

executive
#38

Right. No, that's a fair question. And basically, what I've been attempting to get across throughout this presentation is that we have -- my presence here is tied to the commercialization piece. That's the reason I'm here. That's what I signed up for with this job. That's what the shareholders are after. That's where the 100% focus is. And you could argue that's what everyone claims. And probably they do, right? But my view is that we are razor-focused on -- laser-focus might be a better way to put it on making sure we're having conversations in a way that matters for the customers we're speaking with, that we're talking to the right people, and that the structured processes put in place are very particular. And they use networks. We're very glad to use networks and introductions, and it's always simpler when you have an introduction, particularly in places like the U.S. and South Korea, too, in particular, and India as well. So the answer is what's different? Well, we've heard what has been said that you really must deliver, and everything is very, very, very focused on that. There is -- we've essentially streamlined and shed anything that would not -- that could potentially disrupt that. And here we sit at a very interesting and important time for the company.

Merrill Gray

executive
#39

We have to prove we can deliver. That's clear to me. But yes, we've done everything within our power with the team to get samples to the right — into the hands of the right people who want to buy our products.

Simon Hinsley

unknown
#40

Thank you, Merrill. That brings the question-and-answer portion to a close. I'll turn things back over to you now for a few short closing comments.

Merrill Gray

executive
#41

Yes. So once more, many thanks for being with me today. I'm really glad to field whatever questions come up after this webinar. And naturally, we're constantly responding to inquiries that arrive via our investor e-mail. I'd like to express my gratitude once more for the backing you've given me and the team as we push ahead. And we genuinely value that — it isn't something we assume. We regard it as significant and genuine. Sometimes it's tough to stay excited when results take a while to materialize. But there have been moments in the office that felt truly encouraging over the last 6 months, when genuinely strong technical work got done. There's genuine clarity regarding whom we need to talk to, and we are absolutely concentrated on that. So I must phrase this quite carefully, but the moment has really arrived for us to bring some of the excellent things we've been developing into view and for our people to witness that progress is happening. So once again, I appreciate your support. Very glad to be here.

Simon Hinsley

unknown
#42

I appreciate everyone joining us today. And thanks to you, Merrill.

Merrill Gray

executive
#43

I appreciate that.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete AnteoTech Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to AnteoTech Limited earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in AnteoTech Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.